P-Butylaminobenzoyldiethylaminoethyl

P-Butylaminobenzoyldiethylaminoethyl

SCHEMBL503019

CCCCNc1ccc(C(=O)OCCN(CC)CC)cc1

nearest known ligand 0.79

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN1A P35498 5/20 0.79
SCN2A Q99250 5/20 0.79
SCN3A Q9NY46 5/20 0.79
LMNA P02545 4/20 0.79
HRH3 Q9Y5N1 4/20 0.79
CYP1A2 P05177 4/20 0.79
KCNH2 Q12809 4/20 0.79
MAOA P21397 3/20 0.79
SLC6A3 Q01959 3/20 0.79
SCN5A Q14524 2/20 0.79
DRD3 P35462 2/20 0.79
SIGMAR1 Q99720 2/20 0.79
CNR1 P21554 1/20 0.79
DRD4 P21917 1/20 0.79
ACHE P22303 1/20 0.79
HRH2 P25021 1/20 0.79
HTR2A P28223 1/20 0.79
HTR2C P28335 1/20 0.79
MAPK1 P28482 1/20 0.79
NTSR1 P30989 1/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
P-Butylaminobenzoyldiethylaminoethyl SCHEMBL503018 0.99 LMNA (0.79) SCN1ASCN2ASCN3ALMNAHRH3
Tetracaine SCHEMBL1429149 0.90 LMNA (0.79) SCN1ASCN2ASCN3ALMNAHRH3
Tetracaine SCHEMBL34714 0.88 LMNA (1.00) SCN1ASCN2ASCN3ALMNAHRH3
Tetracaine SCHEMBL27896875 0.87 LMNA (0.97) SCN1ASCN2ASCN3ALMNAHRH3
Tetracaine SCHEMBL24370 0.87 LMNA (1.00) SCN1ASCN2ASCN3ALMNAHRH3
Tetracaine SCHEMBL3176478 0.87 LMNA (0.97) SCN1ASCN2ASCN3ALMNAHRH3
Tetracaine SCHEMBL1355595 0.87 LMNA (1.00) SCN1ASCN2ASCN3ALMNAHRH3
Tetracaine SCHEMBL28641231 0.87 LMNA (0.97) SCN1ASCN2ASCN3ALMNAHRH3
Tetracaine SCHEMBL7774179 0.87 LMNA (0.97) SCN1ASCN2ASCN3ALMNAHRH3
SCHEMBL29143435 0.86 LMNA (0.77) SCN1ASCN2ASCN3ALMNAHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260083666-A1 METHOD OF TREATING DISEASE CREWS THOMAS M (US) 2026-03-26 US claimed
US-12329856-B2 Crosslinked hyaluronic acid composition with local anesthetics BIOPOLIMERI S.R.L. (IT) 2025-06-17 US claimed
EP-4362994-B1 CROSSLINKED HYALURONIC ACID COMPOSITION WITH LOCAL ANESTHETICS BIOPOLIMERI S R L (IT) 2025-03-12 EP claimed
US-20240293311-A1 CROSSLINKED HYALURONIC ACID COMPOSITION WITH LOCAL ANESTHETICS BIOPOLIMERI S.R.L. (IT) 2024-09-05 US claimed
EP-4362994-A1 CROSSLINKED HYALURONIC ACID COMPOSITION WITH LOCAL ANESTHETICS Biopolimeri S.r.l. (IT) 2024-05-08 EP claimed
WO-2023003384-A1 POWDER FORMULATION FOR TISSUE REPAIR, PREPARATION METHOD THEREFOR, AND INJECTABLE COMPOSITION FOR TISSUE REPAIR, COMPRISING SAME 주식회사 삼양홀딩스 2023-01-26 WO claimed
WO-2023275241-A1 CROSSLINKED HYALURONIC ACID COMPOSITION WITH LOCAL ANESTHETICS BIOPOLIMERI S.R.L. (IT) 2023-01-05 WO claimed
US-20220387307-A1 METHOD OF TREATING DISEASE CREWS THOMAS M (US) 2022-12-08 US claimed
WO-2022149924-A1 CROSSLINKED HYALURONIC ACID HYDROGEL CROSSLINKED USING CROSSLINKER AND POLYOL, AND FILLER COMPRISING SAME 주식회사 엘지화학 2022-07-14 WO claimed
US-8956160-B2 Device and method for delivering an oral care agent RANIR, LLC (US) 2015-02-17 US claimed
US-20060240037-A1 Methods and compositions for the treatment and prevention of degenerative joint disorders MUCOSAL THERAPEUTICS LLC 2006-10-26 US claimed
US-20060189526-A1 COMPOSITIONS CONTAINING AN INTESTINAL TREFOIL PEPTIDE AND A MUCOADHESIVE THE GENERAL HOSPITAL CORPORATION 2006-08-24 US claimed
US-20060188471-A1 METHODS OF TREATING EPITHELIAL LESIONS THE GENERAL HOSPITAL CORPORATION 2006-08-24 US claimed
EP-1575951-A1 HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY Affinium Pharmaceuticals, Inc. (CA) 2005-09-21 EP claimed
WO-2005000331-A2 COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF DEGENERATIVE JOINT DISORDERS MUCOSAL THERAPEUTICS, INC. (US) 2005-01-06 WO claimed
WO-2004052890-A1 HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY AFFINIUM PHARMACEUTICALS, INC. (CA) 2004-06-24 WO claimed
US-20040005277-A1 Device and method for delivering an oral care agent JPMORGAN CHASE BANK, N.A. 2004-01-08 US claimed
US-20030175360-A1 Symptomatic relief of gastrointestinal disorders LUZZATTI RENZO (US) 2003-09-18 US claimed
WO-2003072048-A2 SYMPTOMATIC RELIEF OF GASTROINTESTINAL DISORDERS PAOLO RENZO LUZZATTI (US) 2003-09-04 WO claimed
US-4105760-A Local anaesthetic salts of chondroitinsulfate compounds SZEJTLI JOZSEF 1978-08-08 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12329856-B2 Crosslinked hyaluronic acid composition with local anesthetics CD44, HCAR3, HCAR2 SCN1A 2618/4885SCN2A 2486/4885SCN3A 2849/4885
US-20260083666-A1 METHOD OF TREATING DISEASE RYR2, RYR1, OPRL1 SCN1A 842/4885SCN2A 904/4885SCN3A 665/4885
US-20220387307-A1 METHOD OF TREATING DISEASE COXFA4L2, ASAH2, OTC SCN1A 1405/4885SCN2A 2081/4885SCN3A 1010/4885
US-20240293311-A1 CROSSLINKED HYALURONIC ACID COMPOSITION WITH LOCAL ANESTHETICS CD44, HCAR3, HCAR2 SCN1A 2618/4885SCN2A 2486/4885SCN3A 2849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.